Skip to content

Studies of Full IMRT and It Combined With Brachytherapy in the part of Dosimetry, Efficacy and Toxicity in Teatment of Local Early Stage Nasopharyngeal

Studies of Full IMRT and It Combined With Brachytherapy in the part of Dosimetry, Efficacy and Toxicity in Teatment of Local Early Stage Nasopharyngeal

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003059
Enrollment
Unknown
Registered
2013-01-28
Start date
2013-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Local Early Stage Nasopharyngea

Interventions

The Group of full IMRT:Radiotherapy Department use IMRT only
The Group of IMRT combine with intracavitary:Radiotherapy Department use IMRT combine with intracavitary

Sponsors

Affiliated Hospital of Luzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The pathological diagnosis of NPC; (2) AJCC2010, UICC2003 installments lower than T2aN0-3M0 (UICC) except oropharyngeal invasion; (3) The primary treatment; (4) Aged 18-70 years old; (5) KPS> 70 points; (6) The normal function of major organs that blood routine and biochemical tests in line with chemoradiotherapy standards; (7) Women of childbearing age must, within 7 days prior to enrollment, pregnancy test (serum or urine), and the results were negative, and are willing to adopt appropriate methods of contraception during the trial. During the trial the use of appropriate methods of contraception for men; (8) Subjects voluntarily participated in the study, written informed consent, compliance, and with the follow-up.

Exclusion criteria

Exclusion criteria: (1) Pregnant and lactating women; (2) Chemoradiotherapy contraindications; (3) Can not be clearly described in the response to treatment; (4) Had received radiotherapy or Inconsistent induction chemotherapy; (5) suffers from mental illness, congestive heart failure, angina, hypertension are not yet control, myocardial infarction less than 6 months, active infectious disease, active peptic ulcer, yet under the control of diabetes and nearly six months taking large dose of the hormone (2 0 mg prednisone or equivalent other hormones) medical complications.

Design outcomes

Primary

MeasureTime frame
Normal organ dose;Short term efficacy;The long-term efficacy;Treatment of toxicit;

Countries

China

Contacts

Public ContactJingbo Wu
Wjb6147@163.com+86 13980257136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026